On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – ...

Alto Neuroscience, Inc. (ANRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NYSE:ANRO) Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 148.7% in ...

Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego -based GMP facility.

Firefly Neuroscience, Inc. (AIFF), a prepackaged software company trading on The Nasdaq Capital Market, has reported significant leadership changes amid challenging market conditions. According to ...

Firefly Neuroscience, Inc. (AIFF), a prepackaged software company trading on The Nasdaq Capital Market, has reported significant leadership changes amid challenging market conditions. According to ...

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025 Initiation of Phase 2 REKINDLE Trial of RE104 in Adjustment ...

About Reunion Neuroscience Inc. Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the ...

Mytos' automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen's investigational cell therapy ANPD001 in Parkinson's disease Mytos, an innovative ...